Quick Facts

• Targeted Conditions: Bronchial asthma (prophylaxis), allergic rhinitis, and allergic conjunctivitis.
• Role in Therapy: Used for the long-term management of specific allergic and respiratory conditions.
• Symptom Relief: Helps in the management of symptoms associated with hay fever and urticaria (hives).

Prosma is a prescription medication utilized in the prophylactic (preventive) management of certain chronic allergic and respiratory conditions. Its approved applications center on offering relief from symptoms related to long-term allergic responses.

The medication is indicated for the long-term prevention of bronchial asthma in all its forms, including mixed asthma. It is important to understand that Prosma is not used to manage an acute asthma episode that has already started, but rather aims to reduce the frequency and severity of future occurrences.

Additionally, Prosma is used for the management of various allergic conditions, providing symptomatic support for:

• Allergic rhinitis (hay fever symptoms).
• Allergic conjunctivitis (eye irritation due to allergies).
• Multi-system allergies and urticaria (hives).

The established medical use of the drug is for the long-term support of these conditions, and it may be administered alongside other ongoing therapies as determined by a healthcare provider.

Regulatory References

1. NIH MedlinePlus guidance

Official Eligibility Rules for Prosma (Ketotifen Fumarate)

The official eligibility for Prosma, which contains Ketotifen Fumarate, is strictly defined by regulatory bodies and varies based on the formulation (Oral or Ophthalmic).

Eligibility is further restricted for soft contact lens wearers using the Ophthalmic solution, who must remove their lenses before instillation due to the preservative Benzalkonium Chloride [NIH - DailyMed].

Prosma Interactions with other medicines and products

The official regulatory documents specify several interaction patterns for Prosma (Ketotifen Fumarate). These interactions are classified based on their potential for pharmacodynamic potentiation, hematological risk, and altered drug clearance.

Systemic Drug-Drug Restrictions Specific combinations are subject to formal restrictions. The simultaneous administration of oral ketotifen and oral antidiabetic agents should be avoided. This restriction is based on reports of a rare risk of a reversible fall in thrombocyte count (thrombocytopenia).

Pharmacodynamic Interactions Co-administration with substances that affect the central nervous system may lead to potentiation of effects. This additive pharmacodynamic interaction applies to CNS depressants, including sedatives, hypnotics, and other antihistamines. Similarly, the effects of alcohol may be potentiated by oral ketotifen, and patients are advised to avoid alcoholic drinks.

Administration and Clearance Constraints For the ophthalmic solution (eye drops), a timing-based rule applies: if used alongside other ocular medications, an interval of at least 5 minutes must separate the administrations. A population-specific constraint is noted for individuals with severe hepatic impairment, where a reduced clearance of ketotifen is likely due to the drug’s reliance on hepatic metabolism. This consideration addresses the potential for increased systemic exposure in this specific patient group.

The mechanism of action involves a dual, complementary approach: the active molecule functions as an antagonist at the Histamine mathbfH1 Receptor (mathbfH1R) and as a stabilizer of the mast cell membrane. The mathbfH1R blockade rapidly interrupts the signaling cascade initiated by circulating histamine. Concurrently, the stabilization effect works to prevent the mathbfCa^2+-dependent degranulation of mast cells, thereby suppressing the cellular release of histamine and other inflammatory mediators like leukotrienes. While mathbfH1R antagonism provides immediate dampening of histamine-driven signaling, the mast cell stabilization is slow to establish, requiring sustained exposure to limit cellular release. This time-dependent process establishes continuous, prophylactic modulation of the body's baseline physiological reactivity. Furthermore, the molecular structure allows for non-selective antagonism of the mathbfH1R which extends to receptors in the Central Nervous System (CNS) due to the compound’s lipophilicity, an intrinsic physiological consequence of the mechanism.

Official Dosing and Administration Guidelines

Prosma (Ketotifen Fumarate) is administered via two primary official routes, the dosing and administration of which are defined for prophylactic use.

Oral Formulation (Tablet/Syrup)

The standard regimen for adults and children over 3 years of age is 1 mg twice daily (bid). The dosage may be increased up to 2 mg twice daily for specific needs. Treatment for children aged 6 months to 3 years uses the syrup form and is administered based on body weight at 0.05 mg/kg twice daily.

• Timing: Oral doses are generally taken with food (morning and evening meals). Starting treatment with a lower dose at night (0.5 mg to 1 mg) for the initial days is a recommended titration method for easily sedated patients.
• Duration: The oral form must be taken continuously for its intended prophylactic effect; the full benefit for conditions like asthma prophylaxis may require 6 to 12 weeks to become established.
• Missed Dose: If a dose is missed, it should be skipped if it is almost time for the next dose; a double dose must not be taken to make up for the omission.

Ophthalmic Formulation (Eye Drops)

The ophthalmic solution is administered topically to the eye. The labeled dose for adults and children aged 3 years and older is 1 drop in the affected eye(s).

• Frequency: The application is limited to twice daily, with a minimum interval of 8 to 12 hours between doses.
• Special Condition: Soft contact lenses must be removed before applying the drops, and re-insertion should be delayed for at least 10 minutes.
• Interactions: If using other eye medications, an interval of at least 5 minutes must be maintained between the applications.

Prosma: Recent Clinical Evidence

Prosma, which contains the active ingredient ketotifen fumarate, is characterized as a non-bronchodilator anti-asthmatic compound with properties related to mast cell stabilization and histamine H1-receptor antagonism. Clinical research primarily focuses on its use in the long-term prophylactic treatment of bronchial asthma and the symptomatic management of allergic conditions such as allergic rhinitis and conjunctivitis.

Efficacy in Asthma Prophylaxis

Long-term clinical trials evaluating ketotifen's role in asthma prophylaxis have been conducted. These studies suggest that the prophylactic activity of the compound may contribute to reduced frequency, severity, and duration of asthma attacks in some patients. In certain cases within the studies, a progressive reduction of dependence on co-administered corticosteroids or bronchodilators was noted.

• Onset of Action: The full prophylactic effect of ketotifen typically takes several weeks to become established. It is important to note that ketotifen is not indicated for and will not stop an established, acute asthma attack.

Safety and Tolerability Profile

In clinical practice and observational data, ketotifen is generally considered to be well-tolerated. The observed side effects are usually mild and often diminish spontaneously after the first few days of use.

Interactions: Researchers have observed a reversible decrease in platelet count in a small number of patients when ketotifen was used concurrently with oral anti-diabetic agents. This observation has led to the suggestion that the concomitant use of these combinations should be carefully reviewed by a healthcare provider.

Common questions about Prosma (FAQ)

Q: What happens if I take too much Prosma (overdose)?

In cases of overdose, official product information describes signs and symptoms that may occur. These can include severe drowsiness, confusion, disorientation, or hyperexcitability, which may be followed by convulsions. Other effects reported in regulatory documents include a fast or irregular heartbeat and loss of consciousness.

Q: What happens if I take Prosma while I am on an oral anti-diabetic drug?

Official regulatory warnings advise against the simultaneous use of oral Prosma and oral antidiabetic agents. This restriction is based on a reported rare risk of a reversible fall in thrombocyte count, a condition known as thrombocytopenia.

Q: Can I use the Prosma eye drops while wearing soft contact lenses?

Official product information states that soft contact lenses should be removed before applying the Prosma ophthalmic solution. The eye drop formulation contains a preservative that may be absorbed by the soft lens material. Re-insertion of the lenses should be delayed for at least 10 minutes following the administration.

Q: What are the common side effects of the Prosma eye drops?

The common side effects listed in official safety documents for the ophthalmic solution include conjunctival hyperaemia (redness of the outer eye), eye irritation, and eye pain. Rhinitis (nasal irritation or inflammation) is also noted as a common side effect.

Q: Do I need a prescription to get Prosma?

The prescription status of Prosma is determined by local regulatory bodies and may vary by country and formulation. The ophthalmic solution (eye drops) is widely available over-the-counter (OTC) in many regions. However, the oral tablet or syrup formulation is typically classified as a prescription-only medication (Rx).

The storage and disposal of Prosma (Ketotifen Fumarate) must adhere strictly to official regulatory guidelines.

These instructions, defined by regulatory bodies, ensure the stability and integrity of the medicine and mandate proper handling and disposal practices.